Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Asselain

Showing results (201-210 of 227) with videos related to

Pageof 23
Sort By:
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|November 2, 2010
[The alliance of the parent, child and the nurse to challenge medical error]D Davous, E Seigneur, A Auvrignon, et al.
British Journal of Cancer|November 15, 2000
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancerJ Y Pierga, E Mouret, V Diéras, et al.
Revue De Pneumologie Clinique|December 21, 2010
[Study KBP-2010-CPHG: inclusion of new cases of primary lung cancer diagnosed in general hospital pneumology departments between 1st January and 31 December 2010]M Grivaux, C Locher, P Bombaron, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)C Courtinard, V Barbet, R Schiappa, et al.
The International Journal of Biological Markers|July 5, 2003
Medullary breast carcinoma: prognostic implications of p53 expressionR Dendale, A Vincent-Salomon, E Mouret-Fourme, et al.
Revue Des Maladies Respiratoires|June 22, 2006
[Cohort KBP-2000-CPHG: Evaluation of factors influencing survival in lung cancer]F Blanchon, M Grivaux, M Zureik, et al.
British Journal of Cancer|October 20, 2011
High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancerE Brain, C Levy, D Serin, et al.
ESMO Open|November 11, 2022
Real-world first-line treatment of patients with BRAF<sup>V600E</sup>-mutant metastatic colorectal cancer: the CAPSTAN CRC studyE Martinelli, C Cremolini, T Mazard, et al.
Journal Francais D'Ophtalmologie|July 6, 2000
[Optic neuropathy after proton-beam therapy for malignant choroidal melanoma]A Meyer, C Lévy, J Blondel, et al.
Breast Cancer Research and Treatment|September 5, 2016
BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapyA S Hamy, I Bieche, J Lehmann-Che, et al.
Pageof 23

Showing results (201-210 of 227) with videos related to

Sort By:
Pageof 23
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|November 2, 2010
[The alliance of the parent, child and the nurse to challenge medical error]D Davous, E Seigneur, A Auvrignon, et al.
British Journal of Cancer|November 15, 2000
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancerJ Y Pierga, E Mouret, V Diéras, et al.
Revue De Pneumologie Clinique|December 21, 2010
[Study KBP-2010-CPHG: inclusion of new cases of primary lung cancer diagnosed in general hospital pneumology departments between 1st January and 31 December 2010]M Grivaux, C Locher, P Bombaron, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)C Courtinard, V Barbet, R Schiappa, et al.
The International Journal of Biological Markers|July 5, 2003
Medullary breast carcinoma: prognostic implications of p53 expressionR Dendale, A Vincent-Salomon, E Mouret-Fourme, et al.
Revue Des Maladies Respiratoires|June 22, 2006
[Cohort KBP-2000-CPHG: Evaluation of factors influencing survival in lung cancer]F Blanchon, M Grivaux, M Zureik, et al.
British Journal of Cancer|October 20, 2011
High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancerE Brain, C Levy, D Serin, et al.
ESMO Open|November 11, 2022
Real-world first-line treatment of patients with BRAF<sup>V600E</sup>-mutant metastatic colorectal cancer: the CAPSTAN CRC studyE Martinelli, C Cremolini, T Mazard, et al.
Journal Francais D'Ophtalmologie|July 6, 2000
[Optic neuropathy after proton-beam therapy for malignant choroidal melanoma]A Meyer, C Lévy, J Blondel, et al.
Breast Cancer Research and Treatment|September 5, 2016
BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapyA S Hamy, I Bieche, J Lehmann-Che, et al.
Pageof 23